Methylprednisolone Tablets
-
Upload
achmad-dodi-meidianto -
Category
Documents
-
view
230 -
download
0
Transcript of Methylprednisolone Tablets
-
8/10/2019 Methylprednisolone Tablets
1/17
Methylprednisolone Tablets, USP
Rx Only
DESCRIPTION
Methylprednisolone Tablets contain methylprednisolone hich is a !l"cocorticoid#$l"cocorticoids are adrenocortical steroids, both nat"rally occ"rrin! and synthetic, hich are
readily absorbed %rom the !astrointestinal tract# Methylprednisolone occ"rs as a hite to
practically hite, odorless, crystalline poder# It is sparin!ly sol"ble in alcohol, in dioxane, and
in methanol, sli!htly sol"ble in acetone, and in chloro%orm, and &ery sli!htly sol"ble in ether# It
is practically insol"ble in ater#
The chemical name %or methylprednisolone is pre!na'(,)'diene'*,+'dione, ((, (-, +('
trihydroxy'.' methyl',/.0,((12' and the molec"lar ei!ht is *-)#)3# The str"ct"ral %orm"la isrepresented belo4
C++5*O6
Methylprednisolone Tablets, %or oral administration, are a&ailable as scored tablets in the
%olloin! stren!th4 ) m!# In addition each tablet contains the %olloin! inacti&e in!redients4
http://www.drugs.com/slideshow/2013-top-20-stories-1070 -
8/10/2019 Methylprednisolone Tablets
2/17
-
8/10/2019 Methylprednisolone Tablets
3/17
Psoriatic arthritis
Epicondylitis
;c"te !o"ty arthritis
3.Collagen Diseases
D"rin! an exacerbation or as maintenance therapy in selected cases o%4
Systemic l"p"s erythematos"s
Systemic dermatomyositis /polymyositis2
;c"te rhe"matic carditis
4.Dermatologic Diseases
>"llo"s dermatitis herpeti%ormis
Se&ere erythema m"lti%orme /Ste&ens'?ohnson syndrome2
Se&ere seborrheic dermatitis
Ex%oliati&e dermatitis
Mycosis %"n!oides
Pemphi!"s
Se&ere psoriasis
5.Allergic States
Control o% se&ere or incapacitatin! aller!ic conditions intractable to ade
-
8/10/2019 Methylprednisolone Tablets
4/17
Se&ere ac"te and chronic aller!ic and in%lammatory processes in&ol&in! the eye and its adnexa
s"ch as4
;ller!ic corneal mar!inal "lcers
5erpes 7oster ophthalmic"s
;nterior se!ment in%lammation
Di%%"se posterior "&eitis and choroiditis
Sympathetic ophthalmia
@eratitis
Optic ne"ritis
;ller!ic con:"ncti&itis
Chorioretinitis
Iritis and iridocyclitis
.Respirator! Diseases
Symptomatic sarcoidosis
>erylliosis
Aoe%%lerBs syndrome not mana!eable by other means
"lminatin! or disseminated p"lmonary t"berc"losis hen "sed conc"rrently ith appropriate
antit"berc"lo"s chemotherapy
;spiration pne"monitis
".#ematologic Disorders
Idiopathic thrombocytopenic p"rp"ra in ad"lts
Secondary thrombocytopenia in ad"lts
;c
-
8/10/2019 Methylprednisolone Tablets
5/17
or palliati&e mana!ement o%4
Ae"=emias and lymphomas in ad"lts
;c"te le"=emia o% childhood
1&.Edematous States
To ind"ce a di"resis or remission o% protein"ria in the nephrotic syndrome, itho"t "remia, o%
the idiopathic type or that d"e to l"p"s erythematos"s#
11.'astrointestinal Diseases
To tide the patient o&er a critical period o% the disease in4
Ulcerati&e colitis
Re!ional enteritis
12.%er(ous S!stem
;c"te exacerbations o% m"ltiple sclerosis
13.)iscellaneous
T"berc"lo"s menin!itis ith s"barachnoid bloc= or impendin! bloc= hen "sed conc"rrently
ith appropriate antit"berc"lo"s chemotherapy#
Trichinosis ith ne"rolo!ic or myocardial in&ol&ement#
Contraindications
Systemic %"n!al in%ections and =non hypersensiti&ity to components#
arnin!s
In patients on corticosteroid therapy s"b:ected to "n"s"al stress, increased dosa!e o% rapidly
actin! corticosteroids be%ore, d"rin!, and a%ter the stress%"l sit"ation is indicated#
Corticosteroids may mas= some si!ns o% in%ection, and ne in%ections may appear d"rin! their
"se# There may be decreased resistance and inability to locali7e in%ection hen corticosteroids
are "sed#
Prolon!ed "se o% corticosteroids may prod"ce posterior s"bcaps"lar cataracts, !la"coma ith
possible dama!e to the optic ner&es, and may enhance the establishment o% secondary oc"lar
in%ections d"e to %"n!i or &ir"ses#
-
8/10/2019 Methylprednisolone Tablets
6/17
*sage in pregnanc!+Since ade
-
8/10/2019 Methylprednisolone Tablets
7/17
There is an enhanced e%%ect o% corticosteroids on patients ith hypothyroidism and in those ith
cirrhosis#
Corticosteroids sho"ld be "sed ca"tio"sly in patients ith oc"lar herpes simplex beca"se o%
possible corneal per%oration#
The loest possible dose o% corticosteroid sho"ld be "sed to control the condition "nder
treatment, and hen red"ction in dosa!e is possible, the red"ction sho"ld be !rad"al#
Psychic deran!ements may appear hen corticosteroids are "sed, ran!in! %rom e"phoria,
insomnia, mood sin!s, personality chan!es, and se&ere depression, to %ran= psychotic
mani%estations# ;lso, existin! emotional instability or psychotic tendencies may be a!!ra&ated
by corticosteroids#
;spirin sho"ld be "sed ca"tio"sly in con:"nction ith corticosteroids in hypoprothrombinemia#
Steroids sho"ld be "sed ith ca"tion in nonspeci%ic "lcerati&e colitis, i% there is a probability o%
impendin! per%oration, abscess or other pyo!enic in%ection9 di&ertic"litis9 %resh intestinal
anastomoses9 acti&e or latent peptic "lcer9 renal ins"%%iciency9 hypertension9 osteoporosis9 and
myasthenia !ra&is#
$roth and de&elopment o% in%ants and children on prolon!ed corticosteroid therapy sho"ld be
care%"lly obser&ed#
;ltho"!h controlled clinical trials ha&e shon corticosteroids to be e%%ecti&e in speedin! the
resol"tion o% ac"te exacerbations o% m"ltiple sclerosis, they do not sho that corticosteroids
a%%ect the "ltimate o"tcome or nat"ral history o% the disease# The st"dies do sho that relati&elyhi!h doses o% corticosteroids are necessary to demonstrate a si!ni%icant e%%ect# /see DOSA'E
A%D AD)%SRAO%.
Since complications o% treatment ith !l"cocorticoids are dependent on the si7e o% the dose and
the d"ration o% treatment, a ris=Gbene%it decision m"st be made in each indi&id"al case as to dose
and d"ration o% treatment and as to hether daily or intermittent therapy sho"ld be "sed#
Con&"lsions ha&e been reported ith conc"rrent "se o% methylprednisolone and cyclosporine#
Since conc"rrent "se o% these a!ents res"lts in a m"t"al inhibition o% metabolism, it is possible
that ad&erse e&ents associated ith the indi&id"al "se o% either dr"! may be more apt to occ"r#
In%ormation %or the Patient
Persons ho are on imm"nos"ppressant doses o% corticosteroids sho"ld be arned to a&oid
expos"re to chic=enpox or measles and, i% exposed, to obtain medical ad&ice#
;d&erse Reactions
http://www.drugs.com/pro/methylprednisolone-tablets.html#i4i_dosage_admin_ID_D75AC41D-171F-4AA5-8598-A57608E9800Chttp://www.drugs.com/pro/methylprednisolone-tablets.html#i4i_dosage_admin_ID_D75AC41D-171F-4AA5-8598-A57608E9800Chttp://www.drugs.com/pro/methylprednisolone-tablets.html#i4i_dosage_admin_ID_D75AC41D-171F-4AA5-8598-A57608E9800Chttp://www.drugs.com/pro/methylprednisolone-tablets.html#i4i_dosage_admin_ID_D75AC41D-171F-4AA5-8598-A57608E9800C -
8/10/2019 Methylprednisolone Tablets
8/17
7luid and Electrol!te Distur-ances
Sodi"m retention
Con!esti&e heart %ail"re in s"sceptible patients
5ypertension
l"id retention
Potassi"m loss
5ypo=alemic al=alosis
)usculos0eletal
M"scle ea=ness
Aoss o% m"scle mass
Steroid myopathy
Osteoporosis
ertebral compression %ract"res
;septic necrosis o% %emoral and h"meral heads
Patholo!ic %ract"re o% lon! bones
'astrointestinal
Peptic "lcer ith possible per%oration and hemorrha!e
Pancreatitis
;bdominal distention
Ulcerati&e esopha!itis
Dermatologic
Impaired o"nd healin!
-
8/10/2019 Methylprednisolone Tablets
9/17
Petechiae and ecchymoses
May s"ppress reactions to s=in tests
Thin %ra!ile s=in
acial erythema
Increased seatin!
%eurological
Increased intracranial press"re ith papilledema /pse"do't"mor cerebri2 "s"ally a%ter treatment
Con&"lsions
erti!o
5eadache
Endocrine
De&elopment o% C"shin!oid state
S"ppression o% !roth in children
Secondary adrenocortical and pit"itary "nresponsi&eness, partic"larly in times o% stress, as in
tra"ma, s"r!ery or illness
Menstr"al irre!"larities
Decreased carbohydrate tolerance
Mani%estations o% latent diabetes mellit"s
Increased re
-
8/10/2019 Methylprednisolone Tablets
10/17
Exophthalmos
)eta-olic
Ne!ati&e nitro!en balance d"e to protein catabolism
The %olloin! additional reactions ha&e been reported %olloin! oral as ell as parenteral
therapy4
Urticaria and other aller!ic, anaphylactic or hypersensiti&ity reactions#
Methylprednisolone Tablets Dosa!e and ;dministration
The initial dosa!e o% Methylprednisolone Tablets may &ary %rom ) m! to )3 m! o%
methylprednisolone per day dependin! on the speci%ic disease entity bein! treated# In sit"ations
o% less se&erity loer doses ill !enerally s"%%ice hile in selected patients hi!her initial doses
may be reAlternati(e Da! herap!+;lternati&e day therapy is a corticosteroid dosin! re!imen in
hich tice the "s"al daily dose o% corticoid is administered e&ery other mornin!# The p"rpose
o% this mode o% therapy is to pro&ide the patient re
-
8/10/2019 Methylprednisolone Tablets
11/17
treatment ith the bene%icial e%%ects o% corticoids hile minimi7in! certain "ndesirable e%%ects,
incl"din! pit"itary'adrenal s"ppression, the C"shin!oid state, Corticoid ithdraal symptoms,
and !roth s"ppression in children#
The rationale %or this treatment sched"le is based on to ma:or premises4 /a2 the anti'
in%lammatory or therape"tic e%%ect o% corticoids persists lon!er than their physical presence andmetabolic e%%ects and /b2 administration o% the corticosteroid e&ery other mornin! allos %or
reestablishment o% more nearly normal hypothalamic'pit"itary'adrenal /5P;2 acti&ity on the o%%'
steroid day#
; brie% re&ie o% the 5P; physiolo!y may be help%"l in "nderstandin! this rationale# ;ctin!
primarily thro"!h the hypothalam"s a %all in %ree cortisol stim"lates the pit"itary !land to
prod"ce increasin! amo"nts o% corticotropin /;CT52 hile a rise in %ree cortisol inhibits ;CT5
secretion# Normally the 5P; system is characteri7ed by di"rnal /circadian2 rhythm# Ser"m le&els
o% ;CT5 rise %rom a lo point abo"t ( pm to a pea= le&el abo"t . am# Increasin! le&els o%
;CT5 stim"late adrenal cortical acti&ity res"ltin! in a rise in plasma cortisol ith maximalle&els occ"rrin! beteen + am and 3 am# This rise in cortisol dampens ;CT5 prod"ction and in
t"rn adrenal cortical acti&ity# There is a !rad"al %all in plasma corticoids d"rin! the day ith
loest le&els occ"rrin! abo"t midni!ht#
The di"rnal rhythm o% the 5P; axis is lost in C"shin!8s disease, a syndrome o% adrenal cortical
hyper%"nction characteri7ed by obesity ith centripetal %at distrib"tion, thinnin! o% the s=in ith
easy br"isability, m"scle astin! ith ea=ness, hypertension, latent diabetes, osteoporosis,
electrolyte imbalance, etc# The same clinical %indin!s o% hyperadrenocorticism may be noted
d"rin! lon!'term pharmacolo!ic dose corticoid therapy administered in con&entional daily
di&ided doses# It o"ld appear, then, that a dist"rbance in the di"rnal cycle ith maintenance o%ele&ated corticoid &al"es d"rin! the ni!ht may play a si!ni%icant role in the de&elopment o%
"ndesirable corticoid e%%ects# Escape %rom these constantly ele&ated plasma le&els %or e&en short
periods o% time may be instr"mental in protectin! a!ainst "ndesirable pharmacolo!ic e%%ects#
D"rin! con&entional pharmacolo!ic dose corticosteroid therapy, ;CT5 prod"ction is inhibited
ith s"bse
-
8/10/2019 Methylprednisolone Tablets
12/17
The %olloin! sho"ld be =ept in mind hen considerin! alternate day therapy4
(#
>asic principles and indications %or corticosteroid therapy sho"ld apply# The bene%its o%
;DT sho"ld not enco"ra!e the indiscriminate "se o% steroids#
+#;DT is a therape"tic techni
-
8/10/2019 Methylprednisolone Tablets
13/17
In "sin! ;DT it is important, as in all therape"tic sit"ations to indi&id"ali7e and tailor the
therapy to each patient# Complete control o% symptoms ill not be possible in all patients#
;n explanation o% the bene%its o% ;DT ill help the patient to "nderstand and tolerate the
possible %lare'"p in symptoms hich may occ"r in the latter part o% the o%%'steroid day#
Other symptomatic therapy may be added or increased at this time i% needed#
3#
In the e&ent o% an ac"te %lare'"p o% the disease process, it may be necessary to ret"rn to a
%"ll s"ppressi&e daily di&ided corticoid dose %or control# Once control is a!ain established
alternate day therapy may be reinstit"ted#
H#
;ltho"!h many o% the "ndesirable %eat"res o% corticosteroid therapy can be minimi7ed by
;DT, as in any therape"tic sit"ation, the physician m"st care%"lly ei!h the bene%it'ris=
ratio %or each patient in hom corticoid therapy is bein! considered#
5o is Methylprednisolone Tablets S"pplied
Methylprednisolone Tablets are a&ailable in the %olloin! stren!th and pac=a!e si7e4
4mg/hite, o&al, l"ePoint Aaboratories#
Re&ised4 -G(*
Pac=a!eGAabel Display Panel
-
8/10/2019 Methylprednisolone Tablets
14/17
-
8/10/2019 Methylprednisolone Tablets
15/17
Package/Label Display Panel
Package/Label Display Panel
-
8/10/2019 Methylprednisolone Tablets
16/17
)E#?8:RED%SO8O%Emethylprednisolone tablet
:roduct normation:roduct !pe 5UM;N PRESCRIPTION DRU$
A;>EAtem Code >Source NDC4.3('
Route o Administration OR;A DEA Schedule
Acti(e ngredient@Acti(e )oiet!
ngredient %ame 9asis o Strength Strength)eth!lprednisolone/Methylprednisolone2 Methylprednisolone ) m!
nacti(e ngredientsngredient %ame Strength
Silicon Dioide
Anh!drous 8actose
)agnesium stearate
Cellulose )icrocr!stalline
Sodium laur!l sulate
Starch Corn
-
8/10/2019 Methylprednisolone Tablets
17/17
Sodium Starch 'l!colate !pe A :otato
:roduct CharacteristicsColor 5ITE Score ) pieces
Shape O;A /O&al2 Si/e 3mm
7la(or mprint Code TA(
Contains
:ac0agingtem Code :ac0age Description
1NDC4.3('6'( +( T;>AET in ( >AISTER P;C@
)ar0eting normation)ar0eting Categor! Application %um-er or )onograph Citation )ar0eting Start Date )ar0eting End Date;ND; ;ND;)(3H 3G+G+(*
8a-eler B >l"ePoint Aaboratories /H+H6.(H2
Esta-lishment%ame Address D@7E Operations?U>IA;NT C;DIST; P5;RM;CEUTIC;AS, INC# ++)H6(6 M;NU;CTURE/.3('62
Revised: 08/2013